We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Iq-ai Limited | IQAI | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.50 | 07:39:29 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
| Industry Sector |
|---|
| GENERAL RETAILERS |
| Top Posts |
|---|
Posted at 05/3/2024 11:43 by festario Looks like people are bailing out at a big loss now. Why wouldn't they?Trevor has proved yet again to be entirely untrustworthy to any self respecting investor. The options price is pathetic and gives no incentive whatsoever to develop the business.One rampy RNS, like he's famous for, and both he, Brett Skelly and Mike Schmainda can grab a load of free cash, by converting and flipping the shares instantly. That's after dragging the share price down here deliberately so they could load up. Another massive red flag has been hoisted today. |
Posted at 05/3/2024 08:43 by clocktower Found it yet F?Hulk whichever way you look at it, they are lining their own pockets at small investors expense. Maybe if they had set targets at 5p to receive these shares then you could argue the case but thy are creaming them off now at 1p TB is a disgrace but then it seems anyone connected to the Jersey Tax haven has got to be treated like holding a hot plate for more than a few seconds. |
Posted at 24/2/2024 19:15 by spurs90 Not in the science(imaging biometrics)but I no longer trust Trevor. These last few months have been orchestrated solely for him to do the placing as low as he did. He could possibly face legal repercussions from comments made in the half/final reports. It could be argued he misled investors to buy with those comments and on the other hand offloaded with the knowledge he will buy them back cheaper at 1.5p. If this is the case, that is in my opinion market manipulation and he should face consequences if it’s proven to be true.There is a new updated presentation on the gam trial that was released then taken down. I did manage to watch it once and there’s information in it that could be seen as price sensitive that’s being withheld. Information about them setting up a trial protocol for paediatric glioblastoma phase 1. Also with the January shareholder letter, past years this was worthy of an rns but not this time it was released on a Sunday night on twitter possibly because everyone kept harassing them about them not posting one. In my opinion everything that was in his power to suppress the share price was done to manipulate it to as low as possible in my opinion. Let’s see who took the placing. |
Posted at 03/2/2024 13:27 by festario This is a wonderful article for Glioblastoma sufferers, but terrible news for IQAI investors.Basically it looks like Prof Scolyer has developed an immense leap forward in curing this horrific disease, via immunotherapy.Maybe we have backed the wrong horse? https://www.bbc.co.u |
Posted at 20/12/2023 07:51 by howdlep Here's a ChatGBT summary of the RNS (Regulatory News Service) announcement regarding IQ-AI Ltd's subsidiary, Imaging Biometrics (IB), and the implications of their recent FDA Fast-Track designation for oral gallium maltolate (GaM) in treating glioblastoma (GBM):Summary of RNS: Company Involved: Imaging Biometrics, LLC, a subsidiary of IQ-AI Ltd. Announcement: The U.S. FDA has granted Fast-Track designation to IB's oral gallium maltolate (GaM) for treating adult patients with relapsed or refractory glioblastoma (GBM), IDH-wildtype. Significance of FDA Decision: Reflects the urgency and unmet medical need in treating GBM. Oral GaM has also received Orphan Drug designation, highlighting its potential in addressing this critical area. Benefits of Fast-Track Designation: Enables an accelerated review process with the FDA. This involves increased communication and collaboration, aimed at speeding up the development and approval process. Company's Response: Trevor Brown, CEO of IQ-AI, expressed satisfaction with this milestone and emphasized commitment to working closely with the FDA to fast-track the clinical development of oral GaM. Implications and Bullet Points: Accelerated Development and Approval: Fast-Track designation means quicker development and potential approval of oral GaM, which could lead to faster patient access. Addressing Unmet Medical Needs: GBM is a severe and currently underserved medical condition. This designation underlines the treatment's importance in filling a significant therapeutic gap. Increased FDA Interaction: The designation allows for more frequent communication with the FDA, possibly leading to more efficient development processes. Market Positioning: This milestone enhances the market positioning of IQ-AI and its subsidiary, potentially leading to commercial advantages. Investor Confidence: Such regulatory milestones can positively impact investor confidence, reflecting the potential success and viability of the treatment. Enhanced Corporate Reputation: Receiving Fast-Track status boosts the company's reputation in the biotech and pharmaceutical industry, potentially opening doors for future collaborations and investments. |
Posted at 16/11/2023 13:10 by festario Another of those 'regular' updates please Trev, and make it a good one. Share price is flagging, and no new interest in terms of investors or Twitter followers. |
Posted at 14/11/2023 07:35 by howdlep Yes on the one hand, albeit he can do that anytime. On the other hand, potential investors should beware a huge gap up RNS. It could drop any day. |
Posted at 08/11/2023 11:51 by festario Nail on head Sir! Maybe if Stonechecker and LSN hasn't mysteriously vanished from the Earth too.Remember when Trevor said WOW in that RNS? Serious investors don't forget shenanigans like that. |
Posted at 09/10/2023 17:49 by festario Here's an interesting thing that's just happened.As you know, I like to test the buy and sell limits, with both brokers to get a feel for how the market is moving. Last week, I sold about 700k shares, between 4.6p and 4.2p, to buy them back a few days later, for less money.If they won't let me sell 200k for example at 4.4p, I'd break it down in to smaller orders. Well, Interactive Investors have just messaged me, saying that my irregular selling is a breach of market rules, I am giving a false indication of demand for shares, and may be guilty of market manipulation.If this activity is seen again, they will sanction me (whatever the hell that means) and may close my account! |
Posted at 09/10/2023 10:47 by festario 2 possibilities here, 1, The Orphan Drug status was priced in, as it was a formality, and therefore no new investors are interested. 2, FAB / Trevor are happy to continue selling into any selling price above 4p which is therefore keeping a lid on the price. Disappointing either way. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
